Related Experiment Video
Updated: Oct 8, 2025

Multimodality Diagnosis of Mesenteric Ischemia
Published on: July 21, 2023
[Olmesartan-associated Enteropathy]
Long Zou1, Qiang Wang1, Yue Li1
1Department of Gastroenterology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
Abstract:
Olmesartan,an angiotensin Ⅱ receptor blocker,is a commonly used antihypertensive drug.Several case reports and cohort studies in recent years have described a severe gastrointestinal adverse event with chronic diarrhea,intestinal malabsorption,and weight loss after the administration of olmesartan.In such cases,the patients recovered after discontinuing olmesartan.This adverse effect is called olmesartan-associated enteropathy(OAE).This article reviews the potential pathogenesis and clinical characteristics of OAE,which broadens the disease spectrum for the differential diagnosis of chronic diarrhea and intestinal malabsorption.
Insights
Olmesartan, an antihypertensive drug, can cause severe gastrointestinal issues like chronic diarrhea and weight loss, known as olmesartan-associated enteropathy. Patients recover after stopping the medication, broadening differential diagnoses for malabsorption syndromes.
Area of Science:
- Gastroenterology
- Pharmacology
- Internal Medicine
Background:
- Olmesartan is a widely prescribed angiotensin II receptor blocker for hypertension.
- Recent studies link olmesartan use to severe gastrointestinal adverse events.
- These events include chronic diarrhea, intestinal malabsorption, and weight loss.
Purpose of the Study:
- To review the potential pathogenesis of olmesartan-associated enteropathy (OAE).
- To describe the clinical characteristics of OAE.
- To enhance the differential diagnosis of chronic diarrhea and malabsorption.
Main Methods:
- Review of case reports and cohort studies.
- Analysis of clinical presentations and patient outcomes.
- Discussion of proposed pathophysiological mechanisms.
Main Results:
- Olmesartan administration is associated with a distinct enteropathy (OAE).
- Symptoms include severe diarrhea, malabsorption, and weight loss.
- Discontinuation of olmesartan leads to patient recovery.
Conclusions:
- OAE is a significant adverse effect of olmesartan therapy.
- Recognizing OAE is crucial for accurate diagnosis of unexplained GI symptoms.
- This review expands the understanding of drug-induced enteropathies.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Drugs for Treatment of Ulcerative Colitis in IBD
Antihypertensive Drugs: Potassium-Sparing Diuretics
Renal Drug Excretion: Tubular Secretion
Nephrotic Syndrome I : Introduction

